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coronary angioplasty 
and 34 underwent e 
Elective stentingwas 
In conclusion for this stent prototype, stent thrombosis 
remains a significant problem after stenting for acute 
dissection but not afteer elective use. 
complications can be reduced to acceptable rates 
increasing institutional experience. 
(3.5 - 6.0 mm). implanted in grafts 
m).Themeanminimalluminaldiameter 
acute rhrombotic occlusion 7 p&en& (11%), m333sitating 
reintervention In 4 patients ( leading lo an acute myocardia) 
infarction In 3 patients. Two ue lo an lntracerebral Needing, 
directly related to the anticoag!!!Wn therapy given. 
A! late fdlow-up (3 - 6 months. n = 46), 16 patients (35%) developed a 
restenosis (> 56% DS) within the stent. necessitating reintervention in 15 
patients (PT& n = 11; WA8 group without stent 
related restenosis (n = 30), 14 resslon ol native or 
bypass disease leading to recu pecmris symptoms. 
within 1 lo 24 months. Ten of t further intervention 
Stenting in saphenous corona ss grafts is technically nd offers 
a rr~w possibility in the difficult struggle to manage these with end 
stage coronary art disease. The acute Lhrombotic occlusions and Meeding 
tendency assocht with meticulous anticoagulant treatment cause anxiety 
but might be decreased by better patient s&&on and using newer designed 
stems. The restenosis rate (35%) seems to be lower than after conventional 
PTCA than in venous graft stenosis 
PLASMA EMDOTHELIN CONCEMTRATIO 
UITH CONGESTIVE HEART FAILURE 
Richard J. Rodeheffer, De 
nett 
Congestive heart failure (CHF) is characterized by 
decreased cardiac output and increased peripheral 
vascular resistance. n to be (associated with 
increased sympathetic increases in plasma 
norepinephrine, renin, and arginine vasopressin. The 
degree of activation of these wasoconstrlctor st:.:~~:i 
correlates poorly with the degree r,f heart failure, 
Hence, there is continued interest in identifying 
vasoconstrictors which may contribute to the 
Endothelin (ET) is a peptide 
determine if plasma ET concentrations are increased in 
with a recovery of 86%. Intra- and interassay 
variabilities are 6% and 9% respectively. Plasma ET 
concentrations were determined in a control group of 71 
normal subjects and in 20 patients 
(NYHA Class III-IV). 
ospitalieed for CHF 
The left ventricular ejection 
fraction in CHF patients was 24.i f 2.1%. Plasma ET in 
controls was 7.1 f 0.1 pg/ml and in CHF patients 11.5 f 
0.9 pg/ml (p<O.OOl) n We conclude that CHF in man is 
characterized by elevated plasma ET concentrations and 
that ET may contribute to the increased vascular 
resistance of CHF. 
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in 
its de in the regulation of ‘he 
We tested the hwothesis chat in 
ventricular oacinn for 8 days (Group I, n=7). 
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(#pcO.O5 vs. Baseline, MAP: mean arterial pressure, CO: cardiac output, 
SVR: systemic vascular resistance, PVR: pulmocary vascular resmince, 
tone in experimental CHF. 
